5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Kelly, C. M.; Bowler, T. G.; D'Angelo, S. P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Vonya, T.; Yoon, S. S.; Singer, S.; DeMatteo, R. P.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Restoration of tumor suppression in vivo by systemic delivery of chemically-modified PTEN mRNA nanoparticles
    Meeting Abstract

    Islam, M. A.; Xu, Y.; Zope, H.; Cao, W.; Mahmoudi, M.; Langer, R.; Kantoff, P. W.; Shi, J.; Zetter, B. R.; Farokhzad, O. C.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials
    Meeting Abstract

    Heller, G.; McCornnack, R. T.; Kheoh, T.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Aftab, D. T.; Hirmand, M.; MacLean, D. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer
    Meeting Abstract

    Hearn, J. W. D.; Xie, W.; Nakabayashi, M.; Almassi, N.; Reichard, C. A.; Pomerantz, M.; Kantoff, P. W.; Sharifi, N.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC)
    Meeting Abstract

    Hecht, J. R.; Naing, A.; Falchook, G.; Patel, M. R.; Infante, J. R.; Aljumaily, R.; Wong, D. J. L.; Autio, K. A.; Wainberg, Z. A.; Javle, M. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate
    Meeting Abstract

    Hansen, A. R.; Shapiro, G.; Do, K. T.; Kumar, R.; Martin-Liberal, J.; Higano, C. S.; Wisinski, K. B.; Dean, E. J.; Heath, E. I.; Rathkopf, D. E.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)
    Meeting Abstract

    George, D. J.; Halabi, S.; Starr, M. D.; Hurwitz, H.; Brady, J. C.; Barak, I.; Morris, M. J.; Rini, B. I.; Small, E. J.; Kim, W.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry
    Journal Article

    Francini, E.; Gray, K. P.; Evan, C.; Kaymakcalan, M. D.; Shaw, G. K.; Kantoff, P. W.; Taplin, M. E.; Sweeney, C.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Histologic determinants of long-term overall survival in patients (pts) with germ cell tumors (GCT)
    Meeting Abstract

    Funt, S.; Patil, S.; Feldman, D. R.; Motzer, R. J.; Bajorin, D. F.; Sheinfeld, J.; Tickoo, S.; Reuter, V. E.; Bosl, G. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save